Search results
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 2 days agoPfizer is competing against GSK's Arexvy, which hit the market about the same time in 2023. Moderna...
Pfizer: An Oversold Pharma Stock in Recovery
GuruFocus.com via Yahoo Finance· 2 days agoThis combination caused a mechanical reaction of profit squeeze, which is unlikely to be sustained as inflation stabilizes and Pfizer's revenue sources...
The FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Investor's Business Daily· 16 hours agoBut longer-term sales are expected to be below 2024 estimates. It will be key to watch how the...
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
The Motley Fool via AOL· 3 days agoPfizer Pfizer (NYSE: PFE) also has suffered as demand for coronavirus vaccination declines. The...
FDA approves first RSV vaccine for at-risk adults in their 50s
CBS News· 7 days agovaccine and drugmaker GSK asked the FDA in February to expand approval beyond adults 60 and older,...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 16 hours agoBoth measures beat expectations. Earnings turned around from a year-earlier loss, while sales...
Here's Why Eli Lilly Will Likely Announce a Stock Split
247wallst.com· 3 days agoWith its stock price fast approaching $1000 per share, drugmaker Eli lilly is poised for a forward...
Moderna says combination flu, COVID shot succeeds in study
BioPharma Dive via Yahoo Finance· 4 days agoModerna’s RSV shot, dubbed Mresvia, was cleared by the...older adults. It’s the third to be...
Chutes & Ladders—Sanofi research head Frank Nestle says au revoir
FierceBiotech· 7 days agoPlease send the good word—or the bad—from your shop to Gabrielle Masson and it will be featured here...